Table 2.
Pathology results after 1–2 biopsies before treatment and 1 biopsy during treatment
| Pathology result | Total group (n = 714) | Biopsy performed in a separate session before the ablation procedure (n = 231) | Biopsy performed in same session as the ablation procedure (n = 483) |
|---|---|---|---|
| Malignant | 471 (66.0%) | 145 (62.7%) | 326 (67.5%) |
| B-cell lymphoma | 1 (0.1%) | 0 (0.0%) | 1 (0.2%) |
| Chromophobe | 27 (3.8%) | 6 (2.6%) | 21 (4.3%) |
| Clear cell | 337 (47.2%) | 93 (40.3%) | 244 (50.5%) |
| Eosinophile | 2 (0.3%) | 0 (0.0%) | 2 (0.4%) |
| NOS | 18 (2.5%) | 12 (5.2%) | 6 (1.2%) |
| Papillary | 28 (3.9%) | 15 (6.5%) | 13 (2.7%) |
| Papillary type 1 | 44 (6.2%) | 14 (6.1%) | 30 (6.2%) |
| Papillary type 2 | 13 (1.8%) | 5 (2.2%) | 8 (1.7%) |
| Papillary type 1 + 2 | 1 (0.1%) | 0 (0.0%) | 1 (0.2%) |
| Benign | 127 (17.8%) | 46 (14.6%) | 81 (16.8%) |
| Angiomyolipoma | 24 (3.4%) | 10 (4.3%) | 14 (2.9%) |
| Leiomyoma | 2 (0.3%) | 1 (0.4%) | 1 (0.2%) |
| Oncocytoma | 100 (14.0%) | 34 (14.7%) | 66 (13.7%) |
| Xanthogranuloma | 1 (0.1%) | 1 (0.7%) | 0 (0.0%) |
| Non-diagnostic | 116 (16.2%) | 40 (17.3%) | 76 (15.7%) |
| No diagnosis | 28 (3.9%) | 17 (7.4%) | 11 (2.3%) |
| Of which ‘oncocytic’ | 6 (21.4%) | 2 (11.7%) | 4 (36.3%) |
| Not representative | 38 (5.3%) | 8 (3.5%) | 30 (6.2%) |
| Normal kidney parenchyma | 30 (4.2%) | 5 (2.2%) | 25 (5.2%) |
| Reactive | 20 (2.8%) | 10 (4.3%) | 10 (2.1%) |